Total Payments
$276,484
2024 Payments
$62,002
Companies
11
Transactions
249
Payment Breakdown by Category
Consulting$201,668 (72.9%)
Travel$51,584 (18.7%)
Other$15,349 (5.6%)
Food & Beverage$5,997 (2.2%)
Education$1,886 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $201,668 | 67 | 72.9% |
| Travel and Lodging | $51,584 | 76 | 18.7% |
| Honoraria | $10,500 | 4 | 3.8% |
| Food and Beverage | $5,997 | 93 | 2.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,575 | 4 | 0.9% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $2,180 | 1 | 0.8% |
| Education | $1,886 | 3 | 0.7% |
| Grant | $94.00 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ViiV Healthcare Company | $86,733 | 60 | $0 (2024) |
| Merck Sharp & Dohme LLC | $76,361 | 78 | $0 (2024) |
| Gilead Sciences, Inc. | $39,237 | 43 | $0 (2024) |
| Shionogi Inc | $22,858 | 26 | $0 (2024) |
| EMD Serono, Inc. | $19,515 | 8 | $0 (2024) |
| Theratechnologies Inc. | $18,282 | 24 | $0 (2024) |
| GlaxoSmithKline, LLC. | $5,808 | 1 | $0 (2024) |
| Janssen Products, LP | $4,300 | 5 | $0 (2022) |
| Janssen Scientific Affairs, LLC | $2,274 | 2 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $987.50 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $62,002 | 43 | Merck Sharp & Dohme LLC ($17,465) |
| 2023 | $64,271 | 52 | ViiV Healthcare Company ($28,437) |
| 2022 | $23,611 | 23 | ViiV Healthcare Company ($7,898) |
| 2021 | $13,927 | 9 | ViiV Healthcare Company ($7,885) |
| 2020 | $20,292 | 9 | ViiV Healthcare Company ($11,992) |
| 2019 | $48,688 | 41 | Merck Sharp & Dohme Corporation ($19,036) |
| 2018 | $15,287 | 28 | Merck Sharp & Dohme Corporation ($14,158) |
| 2017 | $28,407 | 44 | Merck Sharp & Dohme Corporation ($8,204) |
All Payment Transactions
249 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Travel and Lodging | In-kind items and services | $64.00 | General |
| Category: COVID-19 | ||||||
| 12/16/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $50.44 | General |
| Category: COVID-19 | ||||||
| 12/16/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Travel and Lodging | In-kind items and services | $27.47 | General |
| Category: COVID-19 | ||||||
| 12/16/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Travel and Lodging | In-kind items and services | $16.24 | General |
| Category: COVID-19 | ||||||
| 12/06/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Consulting Fee | Cash or cash equivalent | $5,150.00 | General |
| Category: COVID-19 | ||||||
| 11/20/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $6,510.00 | General |
| 11/20/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 11/15/2024 | Shionogi Inc | — | Consulting Fee | Cash or cash equivalent | $5,670.00 | General |
| 11/15/2024 | Theratechnologies Inc. | — | Honoraria | Cash or cash equivalent | $1,500.00 | General |
| 11/15/2024 | Shionogi Inc | — | Travel and Lodging | Cash or cash equivalent | $347.42 | General |
| 11/15/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Travel and Lodging | In-kind items and services | $73.13 | General |
| Category: COVID-19 | ||||||
| 11/15/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $59.99 | General |
| Category: COVID-19 | ||||||
| 11/15/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $59.99 | General |
| Category: COVID-19 | ||||||
| 11/15/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $59.99 | General |
| Category: COVID-19 | ||||||
| 11/14/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Travel and Lodging | In-kind items and services | $394.96 | General |
| Category: COVID-19 | ||||||
| 11/14/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Travel and Lodging | In-kind items and services | $336.59 | General |
| Category: COVID-19 | ||||||
| 11/09/2024 | Merck Sharp & Dohme LLC | ISENTRESS (Drug), STEGLATRO, PIFELTRO | Travel and Lodging | In-kind items and services | $323.26 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/08/2024 | Merck Sharp & Dohme LLC | ISENTRESS (Drug), STEGLATRO, PIFELTRO | Travel and Lodging | In-kind items and services | $7,712.80 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/08/2024 | Merck Sharp & Dohme LLC | ISENTRESS (Drug), STEGLATRO, PIFELTRO | Travel and Lodging | In-kind items and services | $323.26 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/08/2024 | Merck Sharp & Dohme LLC | ISENTRESS (Drug), STEGLATRO, PIFELTRO | Travel and Lodging | In-kind items and services | $251.86 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/07/2024 | Merck Sharp & Dohme LLC | ISENTRESS (Drug), STEGLATRO, PIFELTRO | Travel and Lodging | In-kind items and services | $323.26 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/23/2024 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $160.89 | General |
| 10/20/2024 | ViiV Healthcare Company | — | Travel and Lodging | In-kind items and services | $210.17 | General |
| 10/20/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $53.35 | General |
| 10/20/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $38.57 | General |
About Dr. Roger Bedimo, M.D
Dr. Roger Bedimo, M.D is a Infectious Disease healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1508879859.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Roger Bedimo, M.D has received a total of $276,484 in payments from pharmaceutical and medical device companies, with $62,002 received in 2024. These payments were reported across 249 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($201,668).
Ad
Practice Information
- Specialty Infectious Disease
- Location Dallas, TX
- Active Since 08/15/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1508879859
Products in Payments
- DELSTRIGO (Drug) $14,157
- ISENTRESS (Drug) $8,988
- DOVATO (Drug) $7,120
- Veklury (Drug) $6,293
- EGRIFTA SV (Drug) $5,246
- CABENUVA (Biological) $5,222
- SYMTUZA (Drug) $4,300
- Fetroja (Drug) $4,018
- EGRIFTA (Drug) $3,853
- TIVICAY (Drug) $3,782
- SEROSTIM (Drug) $1,244
- SUSTIVA (Drug) $987.50
- TRIUMEQ (Drug) $146.92
- JULUCA (Drug) $94.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Dallas
Elizabeth Race, Md, MD
Infectious Disease — Payments: $1.7M
Infectious Disease $1.7M
Gary Sinclair, Md, MD
Infectious Disease — Payments: $673,747
Infectious Disease $673,747
Han Schmidly
Infectious Disease — Payments: $548,373
Infectious Disease $548,373
Dr. Edward Dominguez, M.d, M.D
Infectious Disease — Payments: $309,485
Infectious Disease $309,485
Christopher Bettacchi, Md, MD
Infectious Disease — Payments: $198,393
Infectious Disease $198,393
Dr. Jason Gillman, Md, MD
Infectious Disease — Payments: $61,274
Infectious Disease $61,274